The Filing Desk

Karyopharm Therapeutics vs Regenxbio

Karyopharm Therapeutics KPTI · Regenxbio RGNX · Biotechnology

Regenxbio reported revenue of $170 million in fiscal 2025, 1.2 times Karyopharm Therapeutics' $146 million in fiscal 2025. Karyopharm Therapeutics' revenue grew 0.6% in its latest year, and Regenxbio's grew 104.5%. Karyopharm Therapeutics had an operating margin of -62.1%, against -94.6% at Regenxbio. Free cash flow was −$75 million at Karyopharm Therapeutics and −$126 million at Regenxbio.

Side by side

Karyopharm TherapeuticsRegenxbio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$146M$170M
Revenue growth0.6%104.5%
Revenue growth a year, last 5 years6.2%2.0%
Gross margin——
Operating margin−62.1%−94.6%
Net margin−134.2%−113.8%
Free cash flow−$75M−$126M
Free cash flow margin−51.6%−74.2%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count129,231.8%4.2%
Last close$0.02$7.18
P/E at the last close——
Insider trades, last 12 months—bought $949,541, sold $939,970
Piotroski F-score2 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Karyopharm TherapeuticsRegenxbio
Operating margin
Percent of revenue
Karyopharm TherapeuticsRegenxbio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Karyopharm TherapeuticsRegenxbio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Karyopharm Therapeutics and Regenxbio pages.